4Escudier B,Szczylik C,Eisen T,et al. Randomized phase Ⅲ trial of the Raf kinase and VEGFR inhibitor sorafenib ( BAY 43-9006 ) in patient with advanced renal cell carcinoma [ J ]. J Clin Oncol, 2005,23 (Suppl) : a4510.
5DAL LAGO L, DHONDT V, AWADA A. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors [ J ]. Oncologist, 2008, 13 (8) :845 - 858.
6GARNETT M J, MARAIS R. Guilty as charged: B-RAF is a human oncogene [ J ]. Cancer Cell,2004,6 (4) :313 - 319.
7WILHELM S M, CARTER C,TANG L,et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis [ J ]. Can Res, 2004,64 ( 19 ) : 7099 - 7109.
8LIU L,CAO Y,CHEN C ,et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC /PRF/5 [ J ]. Can Res,2006,66(24) :11851 - 11858.
9CLARK J W, EDER J P, RYAN D, et al. Safety and pharmacokinetics of the dualaction Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors [ J ]. Clin Can Res, 2005,11 ( 15 ) : 5472 - 5480.
10AWADA A, HENDLISZ A, GIL T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours[J]. Brit J Can , 2005,92(10) : 1855 - 1861.
1Azad N S, Aragon- Ching J B, Dahut W L, et al. Hand foot skinreactionincreases withcumulative sorafenib dose and withcombination anti - vascaular endothelial growth factor therapy[J]. Clin Cancer Res, 2009, 15." 1411.
2Procopio G, Bellmunt J, Dutcher J, et al. Sorafenib tolera- bility in elderly patients with advanced renal cell carcino-ma :results from a large pooled analysis [J]. Br J Cancer, 2013,108(2) :311-318.
